> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-19/
- Published: 2020-10-11T12:00:00.000Z
- Updated: 2026-09-14T16:32:05.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5146336

[**Final Guide on Biological Deviation Reporting**](https://www.fdaweb.com/final-guide-on-biological-deviation-reporting/)  
*Federal Register* notice: FDA makes available a final guidance entitled “Biological Product Deviation Reporting for Blood and Plasma Establishments.” 10/9/2020

[**Info Collection on Device Inspection Feedback**](https://www.fdaweb.com/info-collection-on-device-inspection-feedback/)  
*Federal Register* notice: FDA sends to OMB an proposed information collection entitled “Requests for Nonbinding Feedback After Certain FDA Inspections of Device Establishments.” 10/8/2020

[**Guide on Drug Elemental Impurities**](https://www.fdaweb.com/guide-on-drug-elemental-impurities/)  
*Federal Register* notice: FDA makes available a final guidance entitled “Q3D(R1) Elemental Impurities.” 10/8/2020

[**Comments Reopened on Cannabidiol/Cannabis Data**](https://www.fdaweb.com/comments-reopened-on-cannabidiol-cannabis-data/)  
*Federal Register* notice: FDA reopens the comment period indefinitely on a notice seeking scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. 10/7/2020

[**Draft Guide on Alternate eSubmission Format**](https://www.fdaweb.com/draft-guide-on-alternate-esubmission-format/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Providing Regulatory Submissions in Alternate Electronic Format.” 10/6/2020

[**FDA Withdraws 16 No-Longer-Marketed ANDAs**](https://www.fdaweb.com/fda-withdraws-16-no-longer-marketed-andas/)  
*Federal Register* notice: FDA withdraws approval of 16 ANDAs from multiple applicants after they notified the agency that their drug products were no longer marketed. 10/6/2020